Capivasertib, also known as Truqap, is a kinase inhibitor approved by the FDA in combination with fulvestrant to treat hormone receptor (HR)-positive, HER2-negative breast cancer that is locally advanced or metastatic. It is particularly recommended for cases where breast cancer cells have certain genetic mutations Show Full Answer

Capivasertib, also known as Truqap, is a kinase inhibitor approved by the FDA in combination with fulvestrant to treat hormone receptor (HR)-positive, HER2-negative breast cancer that is locally advanced or metastatic. It is particularly recommended for cases where breast cancer cells have certain genetic mutations (PIK3CA/AKT1/PTEN) and where the cancer has progressed after at least one endocrine-based regimen or recurred within 12 months of completing initial therapy.

Common Side Effects:
- Diarrhea
- Skin reactions
- Nausea
- Fatigue
- Vomiting
- Stomach inflammation

Serious Side Effects:
- High blood glucose (blood sugar)
- Severe diarrhea
- Severe skin reactions
- Potential fetal harm if taken during pregnancy

For more detailed information, you can visit the Truqap website: [Truqap — AstraZeneca](https://www.truqap.com/).

 This AI-generated response comes from MyBCTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Truqap (Capivasertib) for Breast Cancer | MyBCTeam

New Treatments for Metastatic Breast Cancer: Extending Life | MyBCTeam